A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Hematologic Malignancies (HM) Program Bookmark and Share

Hematologic Malignancies (HM) Program

Stephen J. Forman, M.D., Co-leader
Wing-Chung (John) Chan, M.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.

The long-term goal of the Hematologic Malignancies (HM) Program is to improve outcomes for patients with leukemia, lymphoma, Hodgkin's disease and multiple myeloma. HM integrates basic, translational and clinical research related to the pathogenesis and treatment of hematologic malignancies through close collaborations between basic and clinical researchers. The major areas of focus are to (a) expand opportunities and optimize outcomes for potentially curative treatment with autologous and allogeneic transplantation, (b) increase understanding of malignant stem cells in hematologic malignancies to improve cures and c) develop new, nontransplant experimental therapies for hematologic malignancies.

Recently, HM has expanded research in nontransplant therapeutics and leukemia biology. The success of monoclonal antibodies such as Rituxan (rituximab) and Campath (alemtuzumab) in the treatment of chronic lymphocytic leukemia and novel small molecules such as Gleevec (imatinib) in chronic myelogenous leukemia has made this area fertile ground for study.

Clinical and research programs have been established for specific disease entities, including acute and chronic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma.  With clinical and basic scientists working together, this creates an expanded repertoire of studies focused on individual diseases, which complements our transplant modality-driven investigations. The HM Program then shares results of these studies with researchers and clinicians in other Cancer Center Programs.

Program Goals

  •  Develop novel autologous and allogeneic transplant regimens to improve safety and efficacy of treatment, and expand their use to underserved populations including patients with HIV and older people with hematologic malignancy.
  • Study mechanisms regulating  normal and malignant hematopoietic stem cells (HSCs), and develop therapies based on manipulating normal HSCs and interventions targeting malignant stem cells.
  • Develop novel non-transplant therapeutic studies of epigenetic mechanisms, molecular targets of gene expression, RNAi and immune-based treatments.

HM Members' Research
Members of the HM Program design and lead phase I/II clinical trials using novel therapies for hematologic malignancies. The expertise represented by this group includes cytogenetics and molecular diagnostics, pathology, hematopoietic cell transplantation and graft-versus-host disease, gene- and cell-based therapies, stem cell research and biostatistics. Members of this program collaborate closely with other research programs, including Developmental Cancer Therapeutics and Cancer Immunotherapeutics, for development of small molecule- and immunological-based cancer therapeutics.
 

Hematology Phase I/II Clinical Trials Flowcharts

Hematology Phase I/II Clinical Trials Flowcharts City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation would like to inform you of the wide variety of novel treatment protocols available through phase I and II clinical trials at our institution. Listed below are disease-specific flowchart links describing our program's full complement of clinical trial options for hematological malignancies. To identify an appropriate clinical trial for a specific patient, open a flowchart for the disease of interest. Trials are listed on the flowcharts based on patient and disease characteristics. For more in-depth eligibility and treatment information on an individual study, follow the links in each flowchart document to view the study webpage at clinicaltrials.gov or to send an email to the principal investigator.
 

Hematologic Malignancies (HM) Program

Hematologic Malignancies (HM) Program

Stephen J. Forman, M.D., Co-leader
Wing-Chung (John) Chan, M.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.

The long-term goal of the Hematologic Malignancies (HM) Program is to improve outcomes for patients with leukemia, lymphoma, Hodgkin's disease and multiple myeloma. HM integrates basic, translational and clinical research related to the pathogenesis and treatment of hematologic malignancies through close collaborations between basic and clinical researchers. The major areas of focus are to (a) expand opportunities and optimize outcomes for potentially curative treatment with autologous and allogeneic transplantation, (b) increase understanding of malignant stem cells in hematologic malignancies to improve cures and c) develop new, nontransplant experimental therapies for hematologic malignancies.

Recently, HM has expanded research in nontransplant therapeutics and leukemia biology. The success of monoclonal antibodies such as Rituxan (rituximab) and Campath (alemtuzumab) in the treatment of chronic lymphocytic leukemia and novel small molecules such as Gleevec (imatinib) in chronic myelogenous leukemia has made this area fertile ground for study.

Clinical and research programs have been established for specific disease entities, including acute and chronic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma.  With clinical and basic scientists working together, this creates an expanded repertoire of studies focused on individual diseases, which complements our transplant modality-driven investigations. The HM Program then shares results of these studies with researchers and clinicians in other Cancer Center Programs.

Program Goals

  •  Develop novel autologous and allogeneic transplant regimens to improve safety and efficacy of treatment, and expand their use to underserved populations including patients with HIV and older people with hematologic malignancy.
  • Study mechanisms regulating  normal and malignant hematopoietic stem cells (HSCs), and develop therapies based on manipulating normal HSCs and interventions targeting malignant stem cells.
  • Develop novel non-transplant therapeutic studies of epigenetic mechanisms, molecular targets of gene expression, RNAi and immune-based treatments.

HM Members' Research
Members of the HM Program design and lead phase I/II clinical trials using novel therapies for hematologic malignancies. The expertise represented by this group includes cytogenetics and molecular diagnostics, pathology, hematopoietic cell transplantation and graft-versus-host disease, gene- and cell-based therapies, stem cell research and biostatistics. Members of this program collaborate closely with other research programs, including Developmental Cancer Therapeutics and Cancer Immunotherapeutics, for development of small molecule- and immunological-based cancer therapeutics.
 

Hematology Phase I/II Clinical Trials Flowcharts

Hematology Phase I/II Clinical Trials Flowcharts

Hematology Phase I/II Clinical Trials Flowcharts City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation would like to inform you of the wide variety of novel treatment protocols available through phase I and II clinical trials at our institution. Listed below are disease-specific flowchart links describing our program's full complement of clinical trial options for hematological malignancies. To identify an appropriate clinical trial for a specific patient, open a flowchart for the disease of interest. Trials are listed on the flowcharts based on patient and disease characteristics. For more in-depth eligibility and treatment information on an individual study, follow the links in each flowchart document to view the study webpage at clinicaltrials.gov or to send an email to the principal investigator.
 
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Clinical Trials
Our aggressive pursuit to discover better ways to help patients now – not years from now – places us among the leaders worldwide in the administration of clinical trials.
 
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Discover the wide range of progressive cancer treatment options at City of Hope designed to meet the individual needs of each patient. Here, medical research and clinical care are integrated, speeding the application of scientific discoveries toward better, more effective patient cancer treatments.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 
When you support City of Hope, you help us shorten the time it takes to get from bold, innovative ideas to powerful new medical treatments. Make a gift online now.


NEWS & UPDATES
  • Valentine’s Day is synonymous with dinner reservations, red roses, heart-shaped boxes of chocolates and — more often than not — unrealistically high expectations. Managing those expectations is great advice for all couples on Feb. 14 — and is especially important for couples confronting a cancer diagnosis. Focu...
  • With measles, what starts at a theme park in California definitely doesn’t stay at a theme park in California. Since the beginning of the current measles outbreak – traced to an initial exposure at Disneyland or Disney California Adventure during December – more than 100 people have been diagnosed with a diseas...
  • Even the most loving and secure relationship can be rattled by a life-threatening illness. When a woman is diagnosed with breast cancer, research shows one of the most important factors in helping her cope is having a supportive partner. But that partner can struggle with knowing what to say or how to best supp...
  • It’s been more than a century since Nobel Laureate Paul Ehrlich popularized the idea of a “magic bullet” targeting disease. Cancer researchers ever since have remained in hot pursuit of targeted therapies that home in on cancer cells while leaving normal cells unaffected. Linda Malkas, Ph.D., associate chair of...
  • Cancer patients face a daunting journey marked by challenges and uncertainties. For those undergoing bone marrow, or stem cell, transplantation, one complication poses a particular threat — chronic graft-versus-host disease (GVHD). Now, one researcher may have found a better way to control that threat. GVHD res...
  • Michele Dahlstein, a 50-year-old breast cancer survivor from Upland, California, celebrated her last day of chemotherapy on Dec. 30. She shares her story in her own words: I was diagnosed with breast cancer (invasive ductal carcinoma stage 2) on Aug. 11, 2014, after my yearly mammogram at City of Hope’s W...
  • The treatment of urologic cancers, including bladder cancer, is rapidly evolving. Here, urologic oncologic surgeon and kidney stone specialist Donald Hannoun, M.D., an assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope | Antelope Valley, explains the changes in hi...
  • A woman confronting metastatic breast cancer faces challenges that, at the outset, seem overwhelming. Research tells us these patients are especially vulnerable to anxiety, depression, hopelessness and other sources of distress. At the same time, they are asked to make complicated choices about their medical ca...
  • California health officials are opting to be safe rather than sorry when it comes to e-cigarettes. The increasingly popular devices are a public health threat, according to a California Department of Health report released Jan. 28. The department is seeking statewide regulation of e-cigarettes, saying they  emi...
  • “Not beyond us.” On World Cancer Day, researchers and caregivers around the globe are embracing this refrain. Specifically, the day calls for action to support healthier lifestyles, early cancer detection, quality of life and access to care. In a time of impressive scientific discovery and narrowing...
  • With more advanced cancer treatments and therapies saving lives every day, it’s safe to say cancer is “Not beyond us,” the official tagline for this year’s World Cancer Day. This year’s World Cancer Day observance takes place on Wednesday, Feb. 4, and focuses on cancer prevention, detection an...
  • Does our environment increase our risk of cancer? What about plastic bottles, radiation, chemicals, soy products …? Do they cause cancer? With so many cancer fears, rumors and downright urban legends circulating among our friends and colleagues, not to mention in the media and blogosphere, why not ask the...
  • With this week’s World Cancer Day challenging us to think about cancer on a global scale, we should also keep in mind that daily choices affect cancer risk on an individual scale. Simply put, lifestyle changes and everyday actions can reduce your cancer risk and perhaps prevent some cancers. According to ...
  • If you haven’t heard the term “precision medicine,” you will. If you don’t have an opinion about access to it, you will. On Friday, President Barack Obama unveiled details of the Precision Medicine Initiative, an effort intended to accelerate cancer research in a powerful way, giving doctors new knowledge and n...
  • The lack of a practical way to produce and store enough stem cells for larger-scale therapies and clinical trials is creating a bottleneck in stem cell research. A new grant to City of Hope from the California Institute for Regenerative Medicine (CIRM) will help solve that problem. The $899,728 grant, awarded T...